Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 5/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.52 |
| ▸ | PI4KA | P42356 | 2/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | GAPDH | P04406 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | STAT6 | P42226 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15070711 | 0.90 | ADORA3 (0.53) | AHCYADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL16373916 | 0.90 | ADORA3 (0.54) | AHCYADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL16374026 | 0.90 | ADORA3 (0.54) | AHCYADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL31652878 | 0.89 | ADORA3 (0.52) | AHCYADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL15070706 | 0.89 | ADORA3 (0.52) | AHCYADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL17359784 | 0.89 | PRMT5 (0.59) | AHCYADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL20629107 | 0.84 | ADORA3 (0.52) | AHCYADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL15070288 | 0.84 | AHCY (0.45) | AHCYADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL16373932 | 0.84 | AHCY (0.56) | AHCYADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL16374027 | 0.84 | AHCY (0.56) | AHCYADORA3PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3013340-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2021-06-17 | — | — | US | disclosed |
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-RE48171-E1 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200024297-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2020-01-23 | — | — | US | disclosed |
| US-10464965-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10420788-B2 | — | — | 2019-09-24 | — | — | US | disclosed |
| US-10421771-B2 | — | — | 2019-09-24 | — | — | US | disclosed |
| EP-3466959-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9073960-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2015-02-19 | — | — | US | disclosed |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2015-02-19 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| WO-2014209979-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2013142525-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013096679-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464965-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, ADAR | AHCY 575/4885ADORA3 59/4885PI4KA 1437/4885 |
| US-20200024297-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | AHCY 575/4885ADORA3 59/4885PI4KA 1437/4885 |
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, ADAR | AHCY 575/4885ADORA3 59/4885PI4KA 1437/4885 |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | AHCY 575/4885ADORA3 59/4885PI4KA 1437/4885 |
| US-10420788-B2 | — | PNP, ADAR, NT5C2 | AHCY 296/4885ADORA3 61/4885PI4KA 2317/4885 |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | AHCY 575/4885ADORA3 59/4885PI4KA 1437/4885 |
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | AHCY 575/4885ADORA3 59/4885PI4KA 1437/4885 |
| US-10421771-B2 | — | PNP, ADAR, NT5C2 | AHCY 296/4885ADORA3 61/4885PI4KA 2317/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | AHCY 263/4885ADORA3 53/4885PI4KA 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.